Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082212 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00082212 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 25 participants.
The verdict
NCT00082212, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
Interventions
- BIOLOGICAL Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082212
The ClinicalTrials.gov registry entry for NCT00082212 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00082212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082212 about?
NCT00082212 is a clinical study titled "A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma". The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.
What is the current status of trial NCT00082212?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-11. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00082212?
The interventions under investigation include: Cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00082212?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.